Intercept Announces Advanz Pharma To Acquire Ocaliva In Pbc In Markets Outside The U.S. For Up To $450Mm, Including $405Mm Upfront And An Additional $45Mm In Contingent Payments
Intercept Announces Advanz Pharma To Acquire Ocaliva In Pbc In Markets Outside The U.S. For Up To $450Mm, Including $405Mm Upfront And An Additional $45Mm In Contingent Payments
05/05/22, 11:19 AM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept’s international operations, including a license to commercialize Ocaliva® (obeticholic acid) outside of the U.S.
Company Info
Company info
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.